89bio's Pegozafermin Is Now Gaining Momentum
Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.
89bio's SWOT analysis: pegozafermin's potential in MASH and SHTG markets
Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...
Akero raised to Buy at Bank of America after liver drug data
Bank of America upgraded Akero Therapeutics (NASDAQ:AKRO) on Thursday, citing what it called “game-changing” data the company ...
Seeking Alpha17d
89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward
In this article, I noted the prospects that this company is achieving regarding the development of its pipeline drug known as pegozafermin for the treatment of patients with metabolic-associated ...
89bio’s Pegozafermin: Promising Strategic Outlook and Phase 3 Developments
Leerink Partners analyst Thomas Smith has maintained their bullish stance on ETNB stock, giving a Buy rating on January 2.Stay Ahead of the ...
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on ...
89bio Provides Business Update and Outlook for 2025
Completed enrollment in Phase 3 ENTRUST trial in patients with severe hypertriglyceridemia (SHTG); topline 26-week data expected in the second half of 2025 – – The Phase 3 ENLIGHTEN program in ...